Browsing Tag
TACTI-004 trial
1 post
Why Immutep Limited halted its lung cancer trial and how the decision reshapes its immunotherapy strategy (NASDAQ: IMMP)
Immutep Limited halts the TACTI-004 Phase III lung cancer trial. Discover what the futility result means for eftilagimod alfa and LAG-3 immunotherapy.